Home » Stocks » SRNE

Sorrento Therapeutics, Inc. (SRNE)

Stock Price: $6.88 USD -0.32 (-4.44%)
Updated May 10, 2021 2:23 PM EDT - Market open
Market Cap 2.06B
Revenue (ttm) 46.52M
Net Income (ttm) -230.76M
Shares Out 280.60M
EPS (ttm) -0.91
PE Ratio n/a
Forward PE 1.10
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $6.88
Previous Close $7.20
Change ($) -0.32
Change (%) -4.44%
Day's Open 7.19
Day's Range 6.88 - 7.21
Day's Volume 3,474,659
52-Week Range 2.56 - 19.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Sorrento Therapeutics (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

5 days ago - Zacks Investment Research

The FDA has signed off  Sorrento Therapeutics Inc's (NASDAQ: SRNE) IND to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma. STI-3031 is based on Sorrento's G-MAB library that...

1 week ago - Benzinga

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Over the last several months, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and its development partners have advanced into clinical development (P...

1 week ago - GlobeNewsWire

Hint: It's not because of anything the company said or did.

2 weeks ago - The Motley Fool

Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced data from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respir...

2 weeks ago - Benzinga

Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares lost ground Monday with no evident explanation. The stock was trending on StockTwits.

3 weeks ago - Benzinga

PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug ap...

1 month ago - GlobeNewsWire

Which stock has more potential for growth over the next year? Let's look to the stars for an answer.

Other stocks mentioned: VIR
1 month ago - The Motley Fool

Sorrento Therapeutics Inc (NASDAQ: SRNE) has agreed to acquire ACEA Therapeutics Inc in an all-stock deal of $38 million in shares of Sorrento common stock. Sorrento will also pay the ACEA up to $450 mi...

1 month ago - Benzinga

Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared fir...

Other stocks mentioned: IBIO, MRNA, NVAX, OCGN, PPH
1 month ago - InvestorPlace

AROW, BGS, KEX, SRNE, and TOSYY have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2021

Other stocks mentioned: AROW, BGS, KEX
1 month ago - Zacks Investment Research

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today updated positive results from its Phase 1b study of human allogeneic adipose-derived ...

1 month ago - GlobeNewsWire

Because of the pandemic, many so-called Covid stocks enjoyed outsized gains but investors might want to consider trimming their exposure. The post Take Your Profits!

Other stocks mentioned: APT, DOCU, IBIO, MRNA, NVAX, PTON
1 month ago - InvestorPlace

Sorrento Therapeutics stock, a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has fallen by 6% in the last week. But will the company's...

1 month ago - Forbes

SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the first patient has been treated in its Phase 1b Amyloid Light Chain (AL) Amyl...

1 month ago - GlobeNewsWire

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:

1 month ago - GlobeNewsWire

The risk-to-reward proposition has recently gotten a lot better for investors considering BNGO stock. Is it a buy for single digits?

Other stocks mentioned: BFLY
1 month ago - InvestorPlace

The pullback in SRNE stock has cleared 40%. Sorrento has too many ways to win for the stock to stay down forever.

2 months ago - InvestorPlace

The delay of Sorrento Therapeutics' Covid-19 vaccine has weakened SRNE stock, but the company has plenty more in the pipeline. The post Sorrento Therapeutics Is Betting On A Longer Play, So Should You a...

2 months ago - InvestorPlace

China's regulatory authorities have signed off on Lee's Pharmaceutical Holdings Limited's Phase 3 trial evaluating socazolimab in small-cell lung cancer. Lee Pharma has in-licensed socazolimab from Sorr...

2 months ago - Benzinga

SAN DIEGO, March 07, 2021 (GLOBE NEWSWIRE) -- China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharm, HKEX: 950) announced that its anti-PD-L1 antibody, S...

2 months ago - GlobeNewsWire

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conf...

2 months ago - GlobeNewsWire

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

Other stocks mentioned: AGTC, ATOM, AYTU, CODX, CRTX, DVAX
2 months ago - Investors Business Daily

The best time to invest is right now.

Other stocks mentioned: SPY, WMT
2 months ago - The Motley Fool

Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesd...

Other stocks mentioned: KMPH
2 months ago - Benzinga

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has received clearance from the FDA for its Investigational New Drug applicat...

2 months ago - GlobeNewsWire

SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered into ...

2 months ago - GlobeNewsWire

Sorrento Therapeutics (SRNE) closed at $10.97 in the latest trading session, marking a -0.32% move from the prior day.

2 months ago - Zacks Investment Research

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

The biotech certainly has plenty of COVID-19 candidates in the hopper.

2 months ago - The Motley Fool

UPS Airlines pilots are testing themselves for COVID midflight, using a novel rapid antigen device that has yet to be approved by the U.S., and sending the results ahead to Hong Kong in an effort to avo...

Other stocks mentioned: UPS
2 months ago - FreightWaves

In the latest trading session, Sorrento Therapeutics (SRNE) closed at $13.98, marking a -0.71% move from the previous day.

2 months ago - Zacks Investment Research

Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.

2 months ago - Zacks Investment Research

Investors should be cautious until the biotech has data from a controlled study.

2 months ago - The Motley Fool

These biotech companies may be among the winners of the coronavirus treatment race -- if all goes well in clinical trials.

Other stocks mentioned: GME, GSK, LLY, MRNA, VIR
2 months ago - The Motley Fool

SAN DIEGO, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the formation of ADNAB, Inc., a subsidiary Company, that will develop and commercializ...

3 months ago - GlobeNewsWire

The biotech announced promising results for its experimental coronavirus therapy.

3 months ago - The Motley Fool

SAN DIEGO, Jan. 31, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today additional positive results from its Phase 1b study of human allogeneic adipose-derive...

3 months ago - GlobeNewsWire

The company has several promising treatments in its pipeline.

3 months ago - The Motley Fool

With the trading day practically over, the broad markets were sliding into the weekend.

Other stocks mentioned: BIIB, DDD, DUK, F, AKBA, HOG, LXRX ...
3 months ago - 24/7 Wall Street

The biotech reported encouraging early results for one of its experimental COVID-19 therapies.

3 months ago - The Motley Fool

SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from its Phase 1b study of human allogeneic adipose-deriv...

3 months ago - GlobeNewsWire

Sorrento Therapeutics stock, a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has rallied by a solid 42% over the last 10 trading days,...

3 months ago - Forbes

Can this biotech finally demonstrate progress in its COVID-19 pipeline before it's too late?

3 months ago - The Motley Fool

Sorrento Therapeutics, Inc. (SRNE) CEO Henry Ji Presents at B. Riley Virtual Oncology Conference (Transcript)

3 months ago - Seeking Alpha

The biotech announced the presentation of encouraging data for its experimental COVID-19 antibody therapy STI-2020.

3 months ago - The Motley Fool

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation surveill...

3 months ago - GlobeNewsWire

Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming confe...

3 months ago - GlobeNewsWire

About SRNE

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody appr... [Read more...]

Industry
Biotechnology
Founded
2006
CEO
Henry Ji
Employees
502
Stock Exchange
NASDAQ
Ticker Symbol
SRNE
Full Company Profile

Financial Performance

In 2020, SRNE's revenue was $39.99 million, an increase of 27.21% compared to the previous year's $31.43 million. Losses were -$298.46 million, 2.19% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for SRNE stock is "Strong Buy." The 12-month stock price forecast is 27.50, which is an increase of 299.71% from the latest price.

Price Target
$27.50
(299.71% upside)
Analyst Consensus: Strong Buy